Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

Trends in Pharmacological Sciences

Volumn 29, Issue 10, 2008, Pages 515-519

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MATUZUMAB; NAVELBINE; PACLITAXEL; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; DRUG CHOICE; DRUG RESEARCH; EARLY CANCER; HUMAN; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 52949105139     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.07.007     Document Type: Review

References (44)

1. Thigpen T., et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 60 Suppl. 8 (1987) 2104-2116
2. Wiltshaw E., et al. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat. Rep. 63 (1979) 1545-1548
3. Neijt J.P., et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J. Clin. Oncol. 5 (1987) 1157-1168
4. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br. J. Cancer 78 (1998) 1479-1487
5. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol. Oncol. Clin. North Am. 17 (2003) 957-968
6. McGuire W.P., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111 (1989) 273-279
7. Thigpen J.T., et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 (1994) 1748-1753
8. ten Bokkel Huinink W., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
9. Gordon A.N., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
10. McGuire W.P., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
11. Piccart M.J., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
12. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360 (2002) 505-515
13. Muggia F.M., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 (2000) 106-115
14. Bookman M., and for the Gynecologic Cancer Intergroup. GOG182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin versus combinations with gemcitabine, pegylated liposomal doxorubicin or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma [abstract]. J. Clin. Oncol. 24 (2006) 5002
15. Spriggs D.R., et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 4466-4471
16. McGuire W.P., et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 1589-1599
17. Ozols R.F., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
18. du Bois A., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
19. Vasey P.A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
20. Elit L., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109 (2007) 692-702
21. Alberts D.S., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
22. Markman M., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
23. Armstrong D.K., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
24. Markman M., and Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J. Clin. Oncol. 24 (2006) 988-994
25. Hakes T.B., et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol. Oncol. 45 (1992) 284-289
26. Markman M., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Gro*up and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
27. Conte P.F., et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy [abstract]. J. Clin. Oncol. 25 (2007) 5505
28. Elit L., et al. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 101 (2004) 1926-1935
29. Swart A.C. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON 1). J. Clin. Oncol. 25 (2007) 5509
30. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
31. Markman M. Why study third-, fourth-, fifth-...line chemotherapy of ovarian cancer?. Gynecol. Oncol. 83 (2001) 449-450
32. Markman M., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
33. The ICON and Collaborators AGO. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
34. Pfisterer J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
35. Vergote I., et al. Single agent, canfosfamide versus pegylated doxorubicin or topotecan in 3rd line treatment of platinum refractory or resistant ovarian cancer: Phase 3 study results [abstract]. J. Clin. Oncol. 25 (2007) LBA5528
36. Markman M., et al. Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. 17 (1999) 1141
37. Bookman M.A., et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 283-290
38. Schilder R.J., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11 (2005) 5539-5548
39. Coleman R.L., et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 101 (2006) 126-131
40. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underling responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
41. Burger R.A., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007) 5165-5171
42. Cannistra S.A., et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. J. Clin. Oncol. 34 (2006) 5006
43. Farmer H., et al. Targeting the DNA repair defect in BRCA mutent cells as a therapeutic strategy. Nature 434 (2005) 917-921
44. Fong P.C., et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase 1 study [abstract]. J. Clin. Oncol. 26 (2008) 5510